Elvitegravir (Dutch Wikipedia)

Analysis of information sources in references of the Wikipedia article "Elvitegravir" in Dutch language version.

refsWebsite

Global rank Dutch rank

4^th place

12^th place

2^nd place

8^th place

2web.archive.org

1^st place

1^st place

low place

low place

3,555^th place

1,847^th place

asm.org

jvi.asm.org

Shimura K, Kodama E, Sakagami Y, et al. (2007). Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137). J Virol 82 (2): 764. PMID 17977962. PMC 2224569. DOI: 10.1128/JVI.01534-07.

doi.org

doi.org

Shimura K, Kodama E, Sakagami Y, et al. (2007). Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137). J Virol 82 (2): 764. PMID 17977962. PMC 2224569. DOI: 10.1128/JVI.01534-07.
Lampiris HW. (2012). Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev Anti Infect Ther 10 (1): 13-20. PMID 22149610. DOI: 10.1586/eri.11.157.
Sax, P. E.; Dejesus, E.; Mills, A.; Zolopa, A.; Cohen, C.; Wohl, D.; Gallant, J. E.; Liu, H. C.; Zhong, L.; Yale, K.; White, K.; Kearney, B. P.; Szwarcberg, J.; Quirk, E.; Cheng, A. K. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. The Lancet 379 (9835): 2439-2448. PMID 22748591. DOI: 10.1016/S0140-6736(12)60917-9.

dx.doi.org

Sax, P. E.; Dejesus, E.; Mills, A.; Zolopa, A.; Cohen, C.; Wohl, D.; Gallant, J. E.; Liu, H. C.; Zhong, L.; Yale, K.; White, K.; Kearney, B. P.; Szwarcberg, J.; Quirk, E.; Cheng, A. K. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. The Lancet 379 (9835): 2439-2448. PMID 22748591. DOI: 10.1016/S0140-6736(12)60917-9.

gilead.com

European Commission Approves Stribild®, a New Single Tablet Regimen for the Treatment of HIV-1 Infection. Persbericht van Gilead Sciences, 28 mei 2013
European Commission Approves Gilead’s Vitekta™, an Integrase Inhibitor for the Treatment of HIV-1 Infection. Persbericht van Gilead Sciences, 18 november 2013

nih.gov

ncbi.nlm.nih.gov

Shimura K, Kodama E, Sakagami Y, et al. (2007). Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137). J Virol 82 (2): 764. PMID 17977962. PMC 2224569. DOI: 10.1128/JVI.01534-07.
Stellbrink HJ (2007). Antiviral drugs in the treatment of AIDS: what is in the pipeline ?. Eur. J. Med. Res. 12 (9): 483–95. PMID 17933730.
Lampiris HW. (2012). Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev Anti Infect Ther 10 (1): 13-20. PMID 22149610. DOI: 10.1586/eri.11.157.
Sax, P. E.; Dejesus, E.; Mills, A.; Zolopa, A.; Cohen, C.; Wohl, D.; Gallant, J. E.; Liu, H. C.; Zhong, L.; Yale, K.; White, K.; Kearney, B. P.; Szwarcberg, J.; Quirk, E.; Cheng, A. K. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. The Lancet 379 (9835): 2439-2448. PMID 22748591. DOI: 10.1016/S0140-6736(12)60917-9.

web.archive.org

Phase III Clinical Trial of Elvitegravir. Persbericht van Gilead Sciences, 22 juli 2008
Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor. Persbericht van Gilead Sciences, 22 maart 2008